Holen Sie sich die Stockscreener-App
2.44
6.87%
-0.18
Handel nachbörslich:
2.42
-0.02
-0.82%
Schlusskurs vom Vortag:
$2.62
Offen:
$2.7
24-Stunden-Volumen:
212.89K
Relative Volume:
0.96
Marktkapitalisierung:
$308.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-70.78M
KGV:
-4.3571
EPS:
-0.56
Netto-Cashflow:
$-61.27M
1W Leistung:
+0.83%
1M Leistung:
+20.79%
6M Leistung:
+269.14%
1J Leistung:
+103.33%
1-Tages-Spanne:
$2.425
$2.80
1-Wochen-Bereich:
$2.17
$2.80
52-Wochen-Spanne:
$0.62
$3.08
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Firmenname
Nautilus Biotechnology Inc
Sektor
Branche
Telefon
206-333-2001
Adresse
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.44 | 330.92M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-06-27 | Eingeleitet | Guggenheim | Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2022-01-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-02 | Eingeleitet | Cowen | Outperform |
| 2021-08-04 | Eingeleitet | Goldman | Neutral |
| 2021-07-13 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Nautilus Biotechnology Inc Aktie (NAUT) Neueste Nachrichten
Sujal Patel Buys 25,000 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock - MarketBeat
Executive Parag Mallick receives 280,000 stock options at Nautilus (NAUT) - Stock Titan
Nautilus (NAUT) General Counsel receives 160,000-share stock option grant - Stock Titan
What’s the MACD signal for Nautilus Biotechnology Inc.2025 Winners & Losers & Safe Entry Point Identification - mfd.ru
Nautilus Biotechnology names Amber Faust as Vice President of Sales to drive proteomics expansion - Traders Union
NAUT: New proteomics platform promises comprehensive, reproducible protein analysis with broad applications - TradingView
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales - BioSpace
Nautilus Biotechnology appoints Amber Faust as VP of sales By Investing.com - Investing.com India
Nautilus Biotechnology appoints proteomics commercial leader Amber Faust as vice president of sales - marketscreener.com
Nautilus Biotechnology appoints Amber Faust as VP of sales - Investing.com
Sales veteran joins Nautilus to push single-molecule proteomics into labs - Stock Titan
Guggenheim Forecasts Strong Price Appreciation for Nautilus Biotechnology (NASDAQ:NAUT) Stock - Defense World
Aug Big Picture: What are PROFs growth levers2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
NAUT Should I Buy - Intellectia AI
Nautilus Biotechnology (NAUT) Target Price Raised by Guggenheim - GuruFocus
Nautilus debuts Voyager platform in push toward next-gen proteomics - Longevity.Technology
Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00 at Guggenheim - MarketBeat
Nautilus Biotechnology (NAUT) Target Price Raised by Guggenheim | NAUT Stock News - GuruFocus
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology stock price target raised to $4 by Guggenheim - Investing.com Canada
Nautilus (NAUT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Nautilus Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Nautilus Biotechnology Q4 Earnings Call Highlights - MarketBeat
Nautilus projects 15%-20% expense growth in 2026 as early access program ramps up - MSN
Nautilus Biotechnology (NASDAQ:NAUT) Announces Earnings Results - MarketBeat
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results - Investing News Network
Earnings call transcript: Nautilus Biotechnology Q4 2025 shows cost cuts By Investing.com - Investing.com Australia
Earnings call transcript: Nautilus Biotechnology Q4 2025 shows cost cuts - Investing.com Nigeria
BRIEF-Nautilus Biotechnology Q4 EPS USD -0.11 - TradingView
Nautilus Biotechnology Inc. recently stated that the company does not expect to generate substantial revenue from early access program collaborations before 2026. - Bitget
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Nautilus Biotechnology Q4 2025 Earnings Call Transcript - MarketBeat
Market Fear: Whats the RSI of Nautilus Biotechnology Inc stockMarket Risk Report & Capital Protection Trade Alerts - baoquankhu1.vn
Nautilus Biotechnology (NAUT) trims 2025 loss, sees cash runway through 2027 - Stock Titan
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026 - BioSpace
Nautilus Biotechnology IncCommercial launch of Voyager platform expected in late 2026 - marketscreener.com
Nautilus Biotechnology, Inc. Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, At US HUPO 2026 - marketscreener.com
Nautilus machine maps 10 billion proteins to study Alzheimer’s - Stock Titan
Ideas Watch: Does Nautilus Biotechnology Inc have a competitive edge2025 Geopolitical Influence & AI Driven Price Forecasts - baoquankhu1.vn
Nautilus Biotechnology (NAUT) to Release Earnings on Thursday - Defense World
Is Nautilus Biotechnology Inc. stock a smart retirement pickMarket Performance Recap & Technical Pattern Alert System - mfd.ru
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference - Bluefield Daily Telegraph
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Decreases By 16.6% - MarketBeat
Will Nautilus Biotechnology Inc. stock hit new highs in YEARWeekly Trend Recap & Proven Capital Preservation Tips - mfd.ru
Pullback Watch: Should I hold or sell Nautilus Biotechnology Inc nowTrade Signal Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
How Nautilus Biotechnology Inc. stock reacts to job market data2025 Risk Factors & Daily Volume Surge Signals - mfd.ru
3 Penny Stocks With Market Caps Over $50M To Watch - simplywall.st
Earnings Miss: Does Nautilus Biotechnology Inc have strong fundamentalsStop Loss & Real-Time Buy Signal Notifications - baoquankhu1.vn
Nautilus Biotechnology explores multiomics to mitigate space travel effects - Traders Union
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Risk Hedge: Is GP Act III Acquisition Corp Equity Warrant stock suitable for long term investing - baoquankhu1.vn
Finanzdaten der Nautilus Biotechnology Inc-Aktie (NAUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nautilus Biotechnology Inc-Aktie (NAUT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Suzuki Kentaro | Chief Marketing Officer |
Nov 06 '25 |
Buy |
1.49 |
4,000 |
5,960 |
4,000 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 05 '25 |
Buy |
0.67 |
116,500 |
78,544 |
10,258,221 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
| Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
| Mowry Anna | CFO and Treasurer |
May 29 '25 |
Buy |
0.77 |
15,000 |
11,488 |
83,000 |
| Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):